Literature DB >> 8870841

The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons.

W A Paxton1, T Dragic, R A Koup, J P Moore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8870841     DOI： 10.1089/aid.1996.12.1203

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  12 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

Review 2.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Authors:  M R Boyd; K R Gustafson; J B McMahon; R H Shoemaker; B R O'Keefe; T Mori; R J Gulakowski; L Wu; M I Rivera; C M Laurencot; M J Currens; J H Cardellina; R W Buckheit; P L Nara; L K Pannell; R C Sowder; L E Henderson
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3).

Authors:  D Hammache; N Yahi; M Maresca; G Piéroni; J Fantini
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP.

Authors:  Carol-Ann Amella; Barbara Sherry; David H Shepp; Helena Schmidtmayerova
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.

Authors:  Surender Khurana; Michael Kennedy; Lisa R King; Hana Golding
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

Authors:  Pavel Pugach; Andre J Marozsan; Thomas J Ketas; Elissa L Landes; John P Moore; Shawn E Kuhmann
Journal:  Virology       Date:  2006-12-12       Impact factor: 3.616

8.  Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities.

Authors:  C Guillon; M E van der Ende; P H Boers; R A Gruters; M Schutten; A D Osterhaus
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 9.  Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele.

Authors:  J M McNicholl; D K Smith; S H Qari; T Hodge
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

10.  A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4.

Authors:  A McKnight; M T Dittmar; J Moniz-Periera; K Ariyoshi; J D Reeves; S Hibbitts; D Whitby; E Aarons; A E Proudfoot; H Whittle; P R Clapham
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.